



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 October 2020
EMA/CHMP/544470/2020
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Vimpat lacosamide

On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Vimpat. The marketing authorisation holder for this medicinal product is UCB Pharma S.A.

The CHMP adopted a new indication for the use of Vimpat as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in patients from 4 years of age with idiopathic generalised epilepsy.

For information, the full indications for Vimpat will be as follows:²

Vimpat is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Vimpat is indicated as adjunctive therapy

- in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
- **in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.**

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in **bold**

